Genotypic and phenotypic resistance to stavudine after long-term monotherapy

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 183-186

  Soriano, Vincent ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS ENZYME; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; VIREMIA; VIRUS GENE;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MUTATION; PHENOTYPE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STAVUDINE;

EID: 17344372117     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Murray H, Squires K, Weiss W, Steda S, Sacks H, Hassett J, Gross A, Anderson R & Dunkle L. Stavudine in patients with AIDS an AIDS-related complex: AIDS Clinical Trial Group 089. Journal of Infectious Diseases 1995; 171 (Suppl. 2):S123-S130.
2. Dudley M, Graham K & Kaul S. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. Journal of Infectious Diseases 1992; 166:480-485.
3. Len A & Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51:846-864.
4. Villalba N, Soriano V, Gómez-Cano M, Castilla J, Mas A & González-Lahoz J. Short-term efficacy and safety of stavudine in pretreated HIV-infected patients. Antiviral Therapy 1997; 2:185-189.
5. Spruance S, Pavia A, Mellors J, Murphy R, Gathe J, Stool E, Jemsek J, Dellamonica P, Cross A & Dunkle L. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Annals of Internal Medicine 1997; 126:355-363.
6. Lin P, Samanta H, Rove R, Patick A, Trimble J, Bechtold C, Revie D, Khan N, Federici M, Li H, Lee A, Anderson R & Colonno R. Genotypic and phenotypic analysis of HIV type 1 isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 1994; 170:1157-1164.
7. Lacey S & Larder B. Novel mutation (V75T) in HIV-1 type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2'-3'-dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy 1994; 38:1428-1432.
8. De Wit S, Papadopolus A, Debier M, Sommereijns B & Clumeck N. CD4 response to monotherapy with stavudine in zidovudine experienced patients: lack of correlation of V75T mutation with therapeutical failure. AIDS 1996; 10 (Suppl. 2):20.
9. Soriano V, Dietrich U, Villalba N, Immelmann A, Gil-Aguado A, Echevarnía S, Clotet B, Ocaña I, Santamaría JM, Bouza E, Bonora V, Gatell JM & González-Lahoz J. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997; 11:696-697.
10. Soriano V, Villalba N, Dietrich U, García-Lerma G, . Castilla J, Immelmann A, Gil-Aguado A, Echevarría S, Clotet B, Ocaña I, Santamaría JM, Bouza E, Bonora V, Alcácer F, Gatell JM, Heneine W & González-Lahoz J. Lack of genotypic resistance to stavudine (d4T) after 2 years' monotherapy. Antiviral Therapy 1997; 2 (Suppl. 3):71-76.
11. Vandamme A, Schmit J, Van Dooren S, Van Laethem K, Gobbers E, Kok W, Goubau P, Wityrouw M, Peetermans W, De Clerq E & Desmyter J. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the Amplicor HIV monitor test, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996; 13:127-139.
12. Hubert JJ. Spearman-Karber method. In Bioassay, 1984, 2nd edition, pp. 65-66. Edited by JA de·Dubuque. Hunt Publishing.
13. De Jong M, Veenstra J, Stilianakis N, Schuurman R, Lange J, De Boer R & Boucher C. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV type 1 RNA load suppression by zidovudine. Proceedings of the National Academy of Sciences, USA 1996; 93:5501-5506.
14. Rouleau D, Conway B, Raboud J, Rae S, Fransen S, Shillington A, Zala C, O'Shaughnessy M & Montaner J. Stavudine plus lamivudine in advanced HIV disease: a short-term pilot study. Journal of Infectious Diseases 1997; 176:1156-1160.
15. th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5 1998. Abstract 676.
16. Brandi G, Puddu P, Casabianca A, Cianfriglia M & Magnani M. The inhibitory effect of ddC on human immunodeficiency virus replication diminishes in cells that are chronically exposed to the drug. Antimicrobial Chemistry and Chemotherapy 1997; 8 (Suppl. 2):113-119.
17. Turriziani O, Antonelli G, Focher F, Bambacioni F & Dianzani F. Further study of the mechanism underlying the cellular resistance to AZT. Biochemical & Biophysical Research Communications 1996; 228:797-801.
18. th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5 1998. Abstract 362.